2.97
+0.03(+1.02%)
Currency In USD
| Previous Close | 2.94 |
| Open | 2.91 |
| Day High | 2.99 |
| Day Low | 2.91 |
| 52-Week High | 4.97 |
| 52-Week Low | 1.75 |
| Volume | 21,099 |
| Average Volume | 34,280 |
| Market Cap | 40.74M |
| PE | -1.94 |
| EPS | -1.53 |
| Moving Average 50 Days | 2.79 |
| Moving Average 200 Days | 3.05 |
| Change | 0.03 |
If you invested $1000 in Grace Therapeutics, Inc. (GRCE) since IPO date, it would be worth $986.71 as of June 29, 2025 at a share price of $2.97. Whereas If you bought $1000 worth of Grace Therapeutics, Inc. (GRCE) shares 0 years ago, it would be worth $986.71 as of June 29, 2025 at a share price of $2.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
GlobeNewswire Inc.
Jun 25, 2025 12:00 PM GMT
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trig
Grace Therapeutics to Participate in the 2025 BIO International Conference
GlobeNewswire Inc.
Jun 13, 2025 12:00 PM GMT
PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being d
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
GlobeNewswire Inc.
Apr 09, 2025 12:00 PM GMT
NDA Submission Anticipated Q2 Calendar 2025PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,